210 related articles for article (PubMed ID: 20940402)
1. Enhanced genetic instability and dasatinib sensitivity in mammary tumor cells lacking NEDD9.
Singh MK; Izumchenko E; Klein-Szanto AJ; Egleston BL; Wolfson M; Golemis EA
Cancer Res; 2010 Nov; 70(21):8907-16. PubMed ID: 20940402
[TBL] [Abstract][Full Text] [Related]
2. A requirement for Nedd9 in luminal progenitor cells prior to mammary tumorigenesis in MMTV-HER2/ErbB2 mice.
Little JL; Serzhanova V; Izumchenko E; Egleston BL; Parise E; Klein-Szanto AJ; Loudon G; Shubina M; Seo S; Kurokawa M; Ochs MF; Golemis EA
Oncogene; 2014 Jan; 33(4):411-20. PubMed ID: 23318423
[TBL] [Abstract][Full Text] [Related]
3. NEDD9 promotes oncogenic signaling in mammary tumor development.
Izumchenko E; Singh MK; Plotnikova OV; Tikhmyanova N; Little JL; Serebriiskii IG; Seo S; Kurokawa M; Egleston BL; Klein-Szanto A; Pugacheva EN; Hardy RR; Wolfson M; Connolly DC; Golemis EA
Cancer Res; 2009 Sep; 69(18):7198-206. PubMed ID: 19738060
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo.
Hingorani P; Zhang W; Gorlick R; Kolb EA
Clin Cancer Res; 2009 May; 15(10):3416-22. PubMed ID: 19447875
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
Johnson FM; Saigal B; Talpaz M; Donato NJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784
[TBL] [Abstract][Full Text] [Related]
6. Dasatinib inhibits mammary tumour development in a genetically engineered mouse model.
Karim SA; Creedon H; Patel H; Carragher NO; Morton JP; Muller WJ; Evans TR; Gusterson B; Sansom OJ; Brunton VG
J Pathol; 2013 Aug; 230(4):430-40. PubMed ID: 23616343
[TBL] [Abstract][Full Text] [Related]
7. NEDD9 and BCAR1 negatively regulate E-cadherin membrane localization, and promote E-cadherin degradation.
Tikhmyanova N; Golemis EA
PLoS One; 2011; 6(7):e22102. PubMed ID: 21765937
[TBL] [Abstract][Full Text] [Related]
8. Src kinase determines the dynamic exchange of the docking protein NEDD9 (neural precursor cell expressed developmentally down-regulated gene 9) at focal adhesions.
Bradbury P; Bach CT; Paul A; O'Neill GM
J Biol Chem; 2014 Sep; 289(36):24792-800. PubMed ID: 25059660
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death.
Ratushny V; Pathak HB; Beeharry N; Tikhmyanova N; Xiao F; Li T; Litwin S; Connolly DC; Yen TJ; Weiner LM; Godwin AK; Golemis EA
Oncogene; 2012 Mar; 31(10):1217-27. PubMed ID: 21785464
[TBL] [Abstract][Full Text] [Related]
10. Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia.
Fei F; Stoddart S; Müschen M; Kim YM; Groffen J; Heisterkamp N
Leukemia; 2010 Apr; 24(4):813-20. PubMed ID: 20111071
[TBL] [Abstract][Full Text] [Related]
11. The anticancer effect of PQ1 in the MMTV-PyVT mouse model.
Shishido SN; Delahaye A; Beck A; Nguyen TA
Int J Cancer; 2014 Mar; 134(6):1474-83. PubMed ID: 24038078
[TBL] [Abstract][Full Text] [Related]
12. FAK activates AKT-mTOR signaling to promote the growth and progression of MMTV-Wnt1-driven basal-like mammary tumors.
Paul R; Luo M; Mo X; Lu J; Yeo SK; Guan JL
Breast Cancer Res; 2020 Jun; 22(1):59. PubMed ID: 32493400
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation.
Wang X; Zhou YX; Qiao W; Tominaga Y; Ouchi M; Ouchi T; Deng CX
Oncogene; 2006 Nov; 25(54):7148-58. PubMed ID: 16715125
[TBL] [Abstract][Full Text] [Related]
14. Sam68 haploinsufficiency delays onset of mammary tumorigenesis and metastasis.
Richard S; Vogel G; Huot ME; Guo T; Muller WJ; Lukong KE
Oncogene; 2008 Jan; 27(4):548-56. PubMed ID: 17621265
[TBL] [Abstract][Full Text] [Related]
15. Adiponectin haploinsufficiency promotes mammary tumor development in MMTV-PyVT mice by modulation of phosphatase and tensin homolog activities.
Lam JB; Chow KH; Xu A; Lam KS; Liu J; Wong NS; Moon RT; Shepherd PR; Cooper GJ; Wang Y
PLoS One; 2009; 4(3):e4968. PubMed ID: 19319191
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.
Liu Y; Karaca M; Zhang Z; Gioeli D; Earp HS; Whang YE
Oncogene; 2010 Jun; 29(22):3208-16. PubMed ID: 20383201
[TBL] [Abstract][Full Text] [Related]
17.
Deneka AY; Kopp MC; Nikonova AS; Gaponova AV; Kiseleva AA; Hensley HH; Flieder DB; Serebriiskii IG; Golemis EA
Cancer Res; 2021 Jul; 81(13):3717-3726. PubMed ID: 34006524
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
[TBL] [Abstract][Full Text] [Related]
19. Wnt5a suppresses tumor formation and redirects tumor phenotype in MMTV-Wnt1 tumors.
Easter SL; Mitchell EH; Baxley SE; Desmond R; Frost AR; Serra R
PLoS One; 2014; 9(11):e113247. PubMed ID: 25401739
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
